|
|
| Conference Program |
|
7:00 AM |
REGISTRATION |
|
|
8:00 AM |
WELCOME |
|
|
8:10 AM |
STATE OF
THE LIFE SCIENCES INDUSTRY IN GEORGIA |
|
|
8:30 AM |
THE CONVERGENCE OF BIOTECHNOLOGY, NANOTECHNOLOGY AND ADVANCED COMPUTING: FORGING NEW VISTAS IN HEALTH, ENVIRONMENTAL MANAGEMENT AND NATIONAL SECURITY |
|
|
9:15 AM |
PERSPECTIVES
ON THE FUTURE OF BIOMEDICINE |
|
|
10:00 AM |
EXHIBIT AND POSTER VIEWING / REFRESHMENTS |
|
|
10:30 AM |
CONCURRENT FOCUS SESSION I |
|
| Ia. PERSONALIZED MEDICINE PROMISES TO ADVANCE HEALTH CARE | ||
| Fred Ledley, MD – Moderator; Professor and Chair, Bentley College Breakthrough Life Sciences Tools Enable the Realization of Personalized Medicine What Role Does Government and Public Policy Play An Investor's Perspective |
||
| Ib. GEORGIA PUBLIC COMPANIES ARE CAPTURING WORLD ATTENTION |
||
| Robert J. Gould – Moderator; Vice President Licensing and External Research, Merck & Co., Inc.
William D. Johnston, PhD; President and CEO, Inhibitex, Inc. Russell M. Medford, MD, PhD; President and CEO, AtheroGenics, Inc. Michael K. Steele; Vice President, Business Development, Corautus Genetics Inc. |
||
| Ic. REGULATION AND REIMBURSEMENT OF MODERN MEDICINES | ||
| Dan Myers – Moderator; President and CEO, Alimera Sciences, Inc. A New and Changing FDA Environment for Clinical Trials that will Potentially Change Development Timelines, Number of Patients, and Costs of Trials Insights into Device Development Programs that would Maximize the Possibility of Timely CMS Reimbursement Key Issues Surrounding Technology Transfer and Commercialization as Trials Move Towards Approval and the Critical Considerations When Selecting a Manufacturing Partner |
||
|
11:45 AM |
LUNCH |
|
|
12:45 PM |
WHY BIOTECHNOLOGY NEEDS WORLD CLASS ADVOCACY |
|
|
1:25 PM |
EXHIBIT AND POSTER VIEWING |
|
|
1:45 PM |
CONCURRENT
FOCUS SESSION II |
|
| IIa. CREATING A ROBUST STRATEGY FOR BIODEFENSE |
||
| C. Michael Cassidy – Moderator; President and CEO, Georgia Research Alliance (GRA) George Poste, PhD, DVM; Director, The Biodesign Institute at Arizona State University and Del E. Webb Distinguished Professor of Biology Daniel M. Sosin, MD, MPH; Associate Director for Science, Coordinating Office for TerrorismPreparedness and Emergency Response, Centers for Disease Control and Prevention Mimi Healy, PhD; President and CEO, Bacterial Barcodes, Inc. Gregory Milman, PhD; Director, Office for Innovation and Special Programs Division of Extramural Activities National Institute of Allergy and Infectious Diseases |
||
| IIb. GEORGIA'S NEXT GENERATION OF WORLD-CLASS PUBLIC COMPANIES | ||
| John P. Richard, MBA – Moderator; General Partner, Georgia Venture Partners Dan Myers; President and CEO, Alimera Sciences, Inc. Eric Tomlinson, PhD, DSc; President and CEO, Altea Therapeutics David Stern; President and CEO, CardioMEMS, Inc. |
||
| IIc. THE VALUATION SQUEEZE - IS BIOTHECH'S FINANCIAL MODEL BROKEN? | ||
| Russell H. Plumb, MBA – Moderator; Vice President, Finance and Administration, Chief Financial Officer, Inhibitex, Inc. E. James Streator III; Head of Healthcare Investment Banking, Susquehanna Financial Group, LLP Michael A. Henos, MBA; Managing General Partner, Alliance Technology Ventures LP Stephen R. Biggar, MD, PhD; Principal, Baker Brothers Investments |
||
| IId. HOW GEORGIA'S RESEARCH INSTITUTIONS ARE PIONEERING THE LIFE SCIENCES | ||
| Todd T. Sherer, PhD – Moderator; Assistant Vice President for Research and Director of the Office of Technology Transfer, Emory University Frank G. Stout, MPH; Vice President for Research Administration, Emory University Charles D. Derby, PhD; Associate Dean for Natural and Physical Sciences, Georgia State University Charles L. Liotta, PhD; Vice Provost for Research and Dean of Graduate Studies, Georgia Institute of Technology Barry D. Goldstein, PhD; Provost and Chief Academic Officer, Medical College of Georgia David Lee, PhD; Vice President of Research and Associate Provost, University of Georgia |
||
|
3:00 PM |
EXHIBIT AND POSTER VIEWING / REFRESHMENTS |
|
|
3:15 PM |
Martin A. Wasserman, PhD – Moderator; Senior Vice President of Discovery Research and Chief Scientific Officer, AtheroGenics, Inc. |
|
| • Renowned Scientific Speakers |
||
| A Holistic Approach to Complex Diseases: Genomics, Proteomics and Immune Modulation of Type I Diabetes Jin-Xiong She, PhD; Professor & Director of the Center for Biotechnology & Genomic Medicine, GRA Eminent Scholar in Genomic Medicine, Medical College of Georgia Product Diversification Within a Core Technology Commercial Opportunities Using Human Embryonic Stem Cells in Drug Discovery Biomedical Nanotechnology for Molecular Imaging, Profiling, and Drug Targeting Found in Translation: Novel Therapies in Cardiovascular Medicine |
||
| Joseph M. Patti, MSPH, PhD - Moderator; Vice President Preclinical Development, Chief Scientific Officer and Member of the Board of Directors, Inhibitex, Inc.
• Poster Session |
||
| • Poster Discussions | ||
|
5:20 PM |
CLOSING REMARKS |
|
|
5:30 PM |
GALA PARTY |
|